Methscopolamine API Manufacturers

compare suppliers & get competitive offers

Pharmaoffer_donkere_achtergrond
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Methscopolamine is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Methscopolamine or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Methscopolamine API 13265-10-6?

Description:
Here you will find a list of producers, manufacturers and distributors of Methscopolamine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Methscopolamine 
Synonyms:
Methylscopolamine  
Cas Number:
13265-10-6 
DrugBank number:
DB11315 
Unique Ingredient Identifier:
VDR09VTQ8U

General Description:

Methscopolamine, identified by CAS number 13265-10-6, is a notable compound with significant therapeutic applications. Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.

Pharmacodynamics:

Methscopolamine exerts its therapeutic effects through: Methscopolamine bromide is an anticholinergic agent which possesses most of the pharmacologic actions of that drug class. These include reduction in volume and total acid content of gastric secretion, inhibition of gastrointestinal motility, inhibition of salivary excretion, dilation of the pupil and inhibition of accommodation with resulting blurring of vision. Large doses may result in tachycardia . The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Classification:

Methscopolamine belongs to the class of organic compounds known as beta hydroxy acids and derivatives. These are compounds containing a carboxylic acid substituted with a hydroxyl group on the C3 carbon atom, classified under the direct parent group Beta hydroxy acids and derivatives. This compound is a part of the Organic compounds, falling under the Organic acids and derivatives superclass, and categorized within the Hydroxy acids and derivatives class, specifically within the Beta hydroxy acids and derivatives subclass.

Categories:

Methscopolamine is categorized under the following therapeutic classes: Agents producing tachycardia, Alimentary Tract and Metabolism, Alkaloids, Anticholinergic Agents, Autonomic Agents, Aza Compounds, Azabicyclo Compounds, Belladonna Alkaloids, Semisynthetic, Quaternary Ammonium Compounds, Belladonna and Derivatives, Plain, Drugs for Functional Gastrointestinal Disorders, Muscarinic Antagonists, Mydriatics and Cycloplegics, Ophthalmologicals, Parasympatholytics, Peripheral Nervous System Agents, Scopolamine Derivatives, Sensory Organs, Synthetic Anticholinergics, Quaternary Ammonium Compounds, Tropanes. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Methscopolamine is a type of Antispasmodics


Antispasmodics are a category of pharmaceutical active pharmaceutical ingredients (APIs) commonly used to treat muscle spasms and cramps. They work by targeting and relaxing the smooth muscles found in various organs, including the gastrointestinal tract, urinary tract, and blood vessels.

These APIs exert their effects by inhibiting the excessive contraction of muscles, thereby relieving pain and discomfort associated with spasms. Antispasmodics can be further classified into two main types: antimuscarinics and calcium channel blockers.

Antimuscarinics, such as hyoscine butylbromide and dicyclomine, function by blocking the action of acetylcholine, a neurotransmitter that stimulates muscle contractions. By inhibiting the binding of acetylcholine to its receptors, antimuscarinics help relax the smooth muscles, particularly in the gastrointestinal tract, providing relief from conditions like irritable bowel syndrome and colic.

On the other hand, calcium channel blockers, including diltiazem and nifedipine, work by blocking the influx of calcium ions into muscle cells. This inhibition prevents the contractile proteins in the muscles from interacting, resulting in muscle relaxation. Calcium channel blockers find applications in the treatment of various conditions, including uterine spasms, coronary artery spasms, and hypertension.

Antispasmodics are available in different formulations, including tablets, capsules, and injections, allowing for flexible dosing options. They are typically prescribed by healthcare professionals and should be used under medical supervision to ensure appropriate dosage and minimize potential side effects.

In summary, antispasmodics are a vital category of pharmaceutical APIs that effectively alleviate muscle spasms and cramps. Their mechanism of action involves targeting either muscarinic receptors or calcium channels, depending on the specific type. These medications provide relief to patients suffering from various conditions involving excessive muscle contractions.